Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma.

被引：0
|
作者：
Santoni, Matteo
Porta, Camillo
Procopio, Giuseppe
Cerbone, Linda
Basso, Umberto
De Giorgi, Ugo
Rizzo, Mimma
Ortega, Cinzia
Massari, Francesco
Iacovelli, Roberto
di Lorenzo, Giuseppe
Milella, Michele
Sabbatini, Roberto
Atzori, Francesco
De Vivo, Rocco
Berardi, Rossana
Santini, Daniele
Cascinu, Stefano
机构：
[1] Polytech Univ Marche Reg, Azienda Osped Univ, Ospedali Riuniti Umberto I GM Lancisi & G Salesi, Ancona, Italy
[2] IRCCS San Matteo Univ Hosp Fdn, Pavia, Italy
[3] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[4] San Camillo & Forlanini Hosp, Rome, Italy
[5] Ist Oncol Veneto IOV IRCCS, Padua, Italy
[6] IRCCS Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy
[7] AORN Cardarelli, Naples, Italy
[8] Fdn Piemonte Oncol, Inst Canc Res & Treatment, Turin, Italy
[9] Univ Verona, Azienda Osped Univ Integrata, I-37100 Verona, Italy
[10] Univ Naples Federico II, GU Canc Sect, Naples, Italy
[11] Reg Elena Natl Canc Inst, Rome, Italy
[12] Med Oncol Univ, Modena, Italy
[13] AOC Cagliari, Struttura Complessa Oncol Med, Cagliari, Italy
[14] San Bortolo Hosp, Vicenza, Italy
[15] Univ Politecn Marche, AO Osped Riuniti, Clin Oncol Med, Ancona, Italy
[16] Univ Campus BioMed, Dept Med Oncol, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.421
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
421
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Early onset hypothyroidism as a predictor for progression-free survival (PFS) and overall survival (OS) benefit in patients with advanced renal cell carcinoma treated with first-line sunitinib
    Pinto, Alvaro
    Garrido, Maria
    Cruz, Patricia
    Lopez, David
    Zambrana, Francisco
    Aguayo, Cristina
    Fellu, Jaime
    Espinosa, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Progression-free survival (PFS) of first-line VEGF-targeted therapy as a prognostic parameter for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
    Seidel, C.
    Fenner, M.
    Reuter, C. W.
    Ganser, A.
    Gruenwald, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Halabi, S.
    Rini, B. I.
    Stadler, W. M.
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Bevacizumab as first-line therapy in metastatic renal cell carcinoma. Progression-free survival for 3 years
    Pichler, R.
    Horninger, W.
    Aigner, F.
    Heidegger, I.
    UROLOGE, 2016, 55 (03): : 381 - 385
  • [5] The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Castro, Daniela
    Tripathi, Nishita
    Sayegh, Nicolas
    Gebrael, Georges
    Li, Xiaochen
    Meza, Luis
    Zengin, Zeynep
    Chehrazi-Raffle, Alex
    Govindarajan, Ameish
    Dizman, Nazli
    Ebrahimi, Hedyeh
    Chawla, Neal
    Mercier, Benjamin
    Hsu, Joann
    Shi, Jessica
    Philip, Errol
    Bergerot, Cristiane
    Barragan-Carrillo, Regina
    Pal, Sumanta
    ONCOLOGIST, 2023, 28 : S5 - +
  • [6] Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma
    Patil, S.
    Figlin, R. A.
    Hutson, T. E.
    Michaelson, M. D.
    Negrier, S.
    Kim, S. T.
    Huang, X.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2011, 22 (02) : 295 - 300
  • [7] Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting
    Nikic, Predrag
    Babovic, Nada
    Dzamic, Zoran
    Salma, Svetlana
    Stojanovic, Vesna
    Matkovic, Suzana
    Pejcic, Zoran
    Juskic, Kristina
    Soldatovic, Ivan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [8] Progression-free survival (PFS) and overall survival (OS) across ethnicities for patients with metastatic renal cell carcinoma (mRCC) receiving targeted therapies (TT) as first-line (1L) treatment
    Salgia, Nicholas
    Dizman, Nazli
    Bergerot, Paulo Gustavo
    Bergerot, Cristiane Decat
    Hsu, Joann
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [9] Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC)
    Verzoni, Elena
    Iacovelli, Roberto
    Rizzo, Mimma
    Felici, Alessandra
    Cascinu, Stefano
    Di Lorenzo, Giuseppe
    Cerbone, Linda
    Ortega, Cinzia
    Masini, Cristina
    Giganti, Maria Olga
    Lorusso, Vito
    Messina, Caterina
    Atzori, Francesco
    De Vincenzo, Fabio
    Sacco, Cosimo
    Boccardo, Francesco
    Valduga, Francesco
    Massari, Francesco
    Tassi, Renato
    Procopio, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [10] Prognostic factors for progression-free survival (PFS), overall survival (OS), and long-term OS (LT-OS) with sunitinib in 1,059 patients, treated on clinical trials, with metastatic renal cell carcinoma (mRCC)
    Motzer, R. J.
    Escudier, B.
    Bukowski, R.
    Rini, B. I.
    Hutson, T. E.
    Barrios, C. H.
    Lin, X.
    Fly, K.
    Matczak, E.
    Gore, M. E.
    BJU INTERNATIONAL, 2012, 109 : 8 - 8
12345